Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Menter

Showing results (91-100 of 117) with videos related to

Pageof 12
Sort By:
The British Journal of Dermatology|August 29, 2012
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging studyK A Papp, A Menter, B Strober, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 20, 2015
Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasisR G Langley, P Rich, A Menter, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 13, 2021
Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysisK Reich, U Mrowietz, A Menter, et al.
Science (New York, N.Y.)|May 20, 1994
Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17qJ Tomfohrde, A Silverman, R Barnes, et al.
The British Journal of Dermatology|May 13, 2005
Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trialS R Feldman, K B Gordon, M Bala, et al.
The British Journal of Dermatology|July 17, 2013
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatmentB Strober, M Buonanno, J D Clark, et al.
Cardiovascular Research|May 1, 1995
Definition of ischaemiaD G Van Wylen, R Baxamusa, J Berge, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 22, 2017
Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)A Menter, R B Warren, R G Langley, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 17, 2017
Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)N H Shear, R Alhusayen, A Fernandez-Obregon, et al.
The British Journal of Dermatology|October 15, 2013
Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomesM Augustin, C Blome, A Costanzo, et al.
Pageof 12

Showing results (91-100 of 117) with videos related to

Sort By:
Pageof 12
The British Journal of Dermatology|August 29, 2012
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging studyK A Papp, A Menter, B Strober, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 20, 2015
Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasisR G Langley, P Rich, A Menter, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 13, 2021
Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysisK Reich, U Mrowietz, A Menter, et al.
Science (New York, N.Y.)|May 20, 1994
Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17qJ Tomfohrde, A Silverman, R Barnes, et al.
The British Journal of Dermatology|May 13, 2005
Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trialS R Feldman, K B Gordon, M Bala, et al.
The British Journal of Dermatology|July 17, 2013
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatmentB Strober, M Buonanno, J D Clark, et al.
Cardiovascular Research|May 1, 1995
Definition of ischaemiaD G Van Wylen, R Baxamusa, J Berge, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 22, 2017
Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)A Menter, R B Warren, R G Langley, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 17, 2017
Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)N H Shear, R Alhusayen, A Fernandez-Obregon, et al.
The British Journal of Dermatology|October 15, 2013
Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomesM Augustin, C Blome, A Costanzo, et al.
Pageof 12